Resources

Research

  • Отчет о “вечнозеленых” патентах в Украине

    В исследовании проанализировано 132 патента на наиболее жизненно важные лекарственные средства в Украине на предмет того, относятся ли они к категории...

  • Evergreening patents in Ukraine

    The research analyzes 132 patents for the most important life-saving medicines in Ukraine on whether they can be considered as...

  • TRIPS-plus analysis Ukraine

    A report on the legal analysis of TRIPS-plus provisions in Ukraine. A look at the legal framework and opportunities for...

  • Analysis of Ukraine’s single-source drug market

    Report on the analysis of the single-source drugs market in Ukraine. A useful tool for treatment activists, and which can...

  • Анализ закупок АРВ-препаратов в Российской Федерации в 2019 году

    Коалиция по готовности к лечению

  • Analysis: ARV procurement, Russia 2019

    ITPC-ru’s 10th year of community-monitoring and analysis in the Russian Federation.

  • Campaign toolkit – our complete guide

    Our toolkit will guide you through all the steps to challenge intellectual property barriers, from the life-cycle of a patent,...

  • Minimum costs to manufacture new treatments for COVID-19

    ‘Repurposing’ existing drugs to treat COVID-19 is vital to reducing mortality and controlling the pandemic. Researchers from the University of...

  • The problem with patents

    This joint policy brief outlines how patents, and their effect on the cost of HIV treatment, threatens to undermine the HIV response in middle-income countries.

  • Access to Hep C treatment among people who inject drugs

    A publication produced by Treatment Action Group (TAG) and Médecins du Monde.

  • Global Survey on Access to and Quality of HIV Treatment and Care

    The 2019 survey focused on barriers to quality HIV care and treatment across 14 low- and middle-income countries covering seven...

  • Activist guide to Hepatitis C diagnostics

    Produced by the Treatment Action Group (TAG), the Activist Guide outlines major barriers to accessing testing technologies and services.